Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/cancer-outcomes-and-all-cause-mortality-in-adults-allocated-to-tBhjFgqItk
References (54)
-
V. Anisimov, L. Berstein, I. Popovich, M. Zabezhinski, P. Egormin, T. Piskunova, A. Semenchenko, M. Tyndyk, M. Yurova, I. Kovalenko, T. Poroshina (2011)
If started early in life, metformin treatment increases life span and postpones tumors in female SHR miceAging (Albany NY), 3
-
M. Monami, C. Lamanna, N. Marchionni, E. Mannucci (2008)
Rosiglitazone and Risk of CancerDiabetes Care, 31
-
D. Cryer, Savian Nicholas, D. Henry, Donna Mills, B. Stadel (2005)
Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study.Diabetes care, 28 3
-
Meei-shyuan Lee, Chih-Cheng Hsu, M. Wahlqvist, Hsin-Ni Tsai, Yu-Hung Chang, Yi-Chen Huang (2011)
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individualsBMC Cancer, 11
-
RR Holman, L Blackwell, IM Stratton, SE Manley, L Tucker, V Frighi (2003)
Six-year results from the Early Diabetes Intervention TrialDiabetic Medicine, 20
-
H. Noto, A. Goto, T. Tsujimoto, Mitsuhiko Noda (2012)
Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysisPLoS ONE, 7
-
R. Turner, C. Cull, V. Frighi, R. Holman (1999)
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.JAMA, 281 21
-
S. Greenland, M. Longnecker (1992)
Methods for trend estimation from summarized dose-response data, with applications to meta-analysis.American journal of epidemiology, 135 11
-
N. Wu, C. Gu, H. Gu, H. Hu, Y. Han, Q. Li (2011)
Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153.Neoplasma, 58 6
-
Cancer outcomes and all - cause mortality in adults allocated to metformin : systematic review and collaborative meta - analysis of randomised clinical trials -
M Monami, C Lamanna, N Marchionni, E Mannucci (2008)
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trialsDiabetes Care, 31
-
RC Turner, CA Cull, V Frighi, RR Holman (1999)
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)J Am Med Assoc, 281
-
Guofang Chen, Shu-hang Xu, K. Renko, M. Derwahl (2012)
Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.The Journal of clinical endocrinology and metabolism, 97 4
-
G. Schernthaner, D. Matthews, B. Charbonnel, Markolf Hanefeld, P. Brunetti (2004)
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.The Journal of clinical endocrinology and metabolism, 89 12
-
G Libby, LA Donnelly, PT Donnan, DR Alessi, AD Morris, JMM Evans (2009)
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetesDiabetes Care, 32
-
S. Yusuf, R. Peto, J. Lewis, R. Collins, P. Sleight (1985)
Beta blockade during and after myocardial infarction: an overview of the randomized trials.Progress in cardiovascular diseases, 27 5
-
S. Coughlin, E. Calle, Lauren Teras, Jennifer Petrelli, M. Thun (2004)
Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.American journal of epidemiology, 159 12
-
G. Libby, L. Donnelly, P. Donnan, D. Alessi, A. Morris, J. Evans (2009)
New Users of Metformin Are at Low Risk of Incident CancerDiabetes Care, 32
-
Steven Kahn, S. Haffner, M. Heise, William Herman, Rury Holman, Nigel Jones, B. Kravitz, J. Lachin, M. O'neill, B. Zinman, G. Viberti (2006)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.The New England journal of medicine, 355 23
-
G. Landman, N. Kleefstra, K. Hateren, K. Groenier, R. Gans, H. Bilo (2009)
Metformin Associated With Lower Cancer Mortality in Type 2 DiabetesDiabetes Care, 33
-
C. Currie, C. Poole, S. Jenkins-Jones, E. Gale, Jeffrey Johnson, C. Morgan (2012)
Mortality After Incident Cancer in People With and Without Type 2 DiabetesDiabetes Care, 35
-
R Ruiter, LE Visser, MPP Herk-Sukel (2012)
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up studyDiabetes Care, 35
-
A. Pfützner, E. Paz-Pacheco, E. Allen, R. Frederich, Roland Chen (2011)
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeksDiabetes, 13
-
A. Decensi, M. Puntoni, P. Goodwin, M. Cazzaniga, A. Gennari, B. Bonanni, S. Gandini (2010)
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysisCancer Prevention Research, 3
-
Sreenivasa Seshasai, S. Kaptoge, Alexander Thompson, E. Angelantonio, Pei Gao, N. Sarwar, P. Whincup, K. Mukamal, R. Gillum, Ingar Holme, I. Njølstad, Astrid Fletcher, Peter Nilsson, S. Lewington, R. Collins, V. Gudnason, Simon Thompson, N. Sattar, Elizabeth Selvin, Frank Hu, J. Danesh (2011)
Diabetes mellitus, fasting glucose, and risk of cause-specific death.The New England journal of medicine, 364 9
-
J. Higgins, D. Altman (2008)
Assessing Risk of Bias in Included Studies -
W. Knowler, E. Barrett-Connor, S. Fowler, R. Hamman, J. Lachin, Elizabeth Walker, David Nathan (2002)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.The New England journal of medicine, 346 6
-
J. Higgins, D. Altman (2008)
Chapter 8: Assessing risk of bias in included studies -
Ross Harris, J. Deeks, D. Altman, M. Bradburn, R. Harbord, J. Sterne (2008)
Metan: Fixed- and Random-Effects Meta-AnalysisThe Stata Journal, 8
-
CJ Currie, CD Poole, S Jenkins-Jones, EAM Gale, JA Johnson, CL Morgan (2012)
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survivalDiabetes Care, 35
-
Turner Turner, R. Holman (1999)
Metformin and Risk of Cardiovascular DiseaseCardiology, 91
-
B. Bao, Zhiwei Wang, Shadan Ali, Aamir Ahmad, A. Azmi, Sanila Sarkar, Sanjeev Banerjee, D. Kong, Yiwei Li, Shivam Thakur, F. Sarkar (2011)
Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer CellsCancer Prevention Research, 5
-
GWD Landman, N Kleefstra, KJJ Hateren, KH Groenier, ROB Gans, HJG Bilo (2010)
Metformin associated with lower cancer mortality in type 2 diabetes: Zodiac-16Diabetes Care, 33
-
R. Ruiter, L. Visser, M. Herk-Sukel, J. Coebergh, H. Haak, P. Geelhoed-Duijvestijn, S. Straus, R. Herings, B. Stricker (2011)
Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea DerivativesDiabetes Care, 35
-
S. Bowker, Yutaka Yasui, P. Veugelers, J. Johnson (2010)
Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposureDiabetologia, 53
-
P. Home, S. Kahn, N. Jones, D. Noronha, H. Beck-Nielsen, G. Viberti, for Committee (2010)
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trialsDiabetologia, 53
-
S. Salpeter, E. Greyber, G. Pasternak, E. Salpeter (2010)
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.The Cochrane database of systematic reviews, 4
-
A. Ramachandran, C. Snehalatha, S. Mary, B. Mukesh, A. Bhaskar, V. Vijay, Indian Programme (2006)
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)Diabetologia, 49
-
S. Ebrahim (2004)
Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?The Lancet, 363
-
P. Moghetti, R. Castello, C. Negri, F. Tosi, F. Perrone, Marco Caputo, E. Zanolin, M. Muggeo (2000)
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.The Journal of clinical endocrinology and metabolism, 85 1
-
A. Arkadieva, A. Mamonov, I. Popovich, V. Anisimov, Mikhel'son Vm, I. Spivak (2011)
Metformin slows down ageing processes at the cellular level in SHR miceCell and Tissue Biology, 5
-
J. Johnson, S. Bowker (2010)
Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trialsDiabetologia, 54
-
A. Ferrara, J. Lewis, C. Quesenberry, Tiffany Peng, B. Strom, S. Eeden, S. Ehrlich, L. Habel (2011)
Cohort Study of Pioglitazone and Cancer Incidence in Patients With DiabetesDiabetes Care, 34
-
M. Hanefeld, P. Brunetti, G. Schernthaner, D. Matthews, B. Charbonnel (2004)
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.Diabetes care, 27 1
-
J. Evans, L. Donnelly, A. Emslie-Smith, D. Alessi, A. Morris (2005)
Metformin and reduced risk of cancer in diabetic patientsBMJ : British Medical Journal, 330
-
P. Muti, F. Berrino, V. Krogh, A. Villarini, M. Barba, S. Strano, G. Blandino (2009)
Metformin, diet and breast cancer: An avenue for chemopreventionCell Cycle, 8
-
R. Turner, R. Holman, I. Stratton, C. Cull, D. Matthews, S. Manley, V. Frighi, D. Wright, A. Neil, E. Kohner, H. Mcelroy, C. Fox, D. Hadden, Grp Ukpds. (1998)
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 352
-
C. Currie, C. Poole, E. Gale (2009)
The influence of glucose-lowering therapies on cancer risk in type 2 diabetesDiabetologia, 52
-
A. Schweizer, A. Couturier, J. Foley, S. Dejager (2007)
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetesDiabetic Medicine, 24
-
P. Home, S. Pocock, H. Beck-Nielsen, P. Curtis, R. Gomis, M. Hanefeld, N. Jones, M. Komajda, J. McMurray (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialThe Lancet, 373
-
D. WILLIAMS-HERMAN, Jeremy Johnson, R. Teng, G. Golm, K. Kaufman, B. Goldstein, J. Amatruda (2010)
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetesDiabetes, 12
-
C. Lefebvre, E. Manheimer, Julie Glanville (2008)
Searching for Studies -
Matthias Schneider, H. Matsuzaki, J. Haorah, A. Ulrich, J. Standop, Xianzhong Ding, T. Adrian, P. Pour, P. Pour (2001)
Prevention of pancreatic cancer induction in hamsters by metformin.Gastroenterology, 120 5
-
Сахарный диабет, Доказательная диабетология (2009)
Combined randomised controlled trial experience of malignancies in studies using insulin glargineDiabetologia, 52
- Publisher
- Springer Journals
- Copyright
- Copyright © 2012 by Springer-Verlag
- Subject
- Medicine & Public Health; Metabolic Diseases; Internal Medicine; Human Physiology
- ISSN
- 0012-186X
- eISSN
- 1432-0428
- DOI
- 10.1007/s00125-012-2653-7
- pmid
- 22875195
- Publisher site
- See Article on Publisher Site
Abstract
Meta-analysis of currently available RCT data does not support the hypothesis that metformin lowers cancer risk by one-third. Eligible trials also showed no significant effect of metformin on all-cause mortality. However, limitations include heterogeneous comparator types, absent cancer data from two trials, and short follow-up, especially for mortality.
Journal
Diabetologia – Springer Journals
Published: Oct 1, 2012